

CMP (Rs) 94

TP (Rs) 112

Maintain Outperformer

Key growth figures	QoQ (%)	YoY (%)		
	Actual	Actual	Our Est	Consensus
Net Sales	17.1	8.7	-8.9	-5.7
EBITDA	10.6	-12.0	-25.4	-18.8
Adj PAT	22.4	-23.0	-41.4	-41.4
EPS (Rs)	22.4	-23.0	-41.4	-41.4

Key Points from Results

- Consolidated revenue grew by 8.7% YoY to Rs 17.6 bn (B&K: 14.7 bn) supported by double digit volume growth (terry towel and rugs segment) and higher mix of innovative products and branded products. This includes currency impact of 4.5% yoy.
- Consolidated EBITDA was adversely impacted higher raw material and power and fuel cost.


Year end	FY16	FY17P	FY18E	FY19E
Valuations				
PER (x)	13.4	10.7	13.5	10.5
PBV (x)	5.0	3.7	3.2	2.6
EV/EBITDA (x)	8.2	7.5	7.9	6.5
Div./Yield (%)	1.3	0.7	1.6	2.0
Key Ratios				
ROE (%)	43.7	37.9	26.3	27.7
ROCE (%)	25.4	19.5	17.6	20.6
Liquidity				
Net Debt/Equity	1.5	1.3	1.0	0.7
Interest cover	6	7	9	13
FCF (Rs mn)	237	-355	5,623	6,978

Commentary and Outlook

- Share of innovative products stood at 36% in FY17 (vs. 34% in FY16) and that of branded sales stood at 16% in FY17 (vs. 13% in FY16). Domestic retail sales witnessed robust growth of 21% in FY17 while Christy UK sales grew by 12% during the same period.
- WLSI announced capex of Rs 7 bn for FY18E which includes enhancing towel capacity to 80000 MT (72000 MT currently) and flooring solutions (7 Mn sq meters capacity).
- The company has guided for topline growth of single digit for FY18E with EBITDA margin of 21-22%.

WLSI's continuous capacity enhancement (towel and rugs), increasing vertical integration, higher share of value added products and branded sales will maintain revenue growth momentum. Fall in the relative debt level (net debt to equity 1.27x in FY17 vs 1.58x in FY16) despite the on-going large capex is the major highlight of the performance. We have revised our estimates taking into consideration the higher capacity guidance and improved performance of the company. The stock currently trades at 10.5x FY19E EPS and 6.5x FY19E EV/EBITDA. We maintain our Outperformer rating on the stock with a revised target price of Rs 112/share (Implied EV/EBITDA of 7.5x on FY19E citing stronger performance and ability to handle cost pressures).





Historic valuation chart



Financial Highlights

(Rs mn)	4QFY16	4QFY17	YoY (%)	3QFY17	QoQ (%)	FY16	FY17P	FY18E	FY19E
Net Sales	16,162	17,572	8.7	15,009	17.1	59,239	66,405	72,437	83,395
EBITDA	4,353	3,829	-12.0	3,463	10.6	15,927	15,834	15,719	18,430
EBITDA Margin	26.9	21.8		23.1		26.9	23.8	21.7	22.1
Other Income	232	156	-33.0	210	-25.8	904	806	846	888
Interest	668	430	-35.6	480	-10.5	2,368	1,583	1,326	1,058
Depreciation	1,036	1,365	31.8	1,305	4.6	3,718	5,054	5,243	5,393
PBT	2,882	2,198	-23.7	2,127	3.4	10,745	5,355	9,996	12,867
Tax	886	653	-26.3	624	4.6	3,254	1,731	2,999	3,860
Adjusted PAT	1,995	1,536	-23.0	1,255	22.4	7,440	8,271	6,997	9,007
NPM (%)	12.3	8.7		8.4		12.6	12.5	9.7	10.8
EPS (Rs)	2.0	1.5	-23.0	1.2	22.4	7.4	8.2	7.0	9.0

Prerna Jhunjhunwala, Nishant Agrawal



Operating cost break-up (% of Sales)

Particulars	Mar-16	Jun-16	Sep-16	Dec-16	Mar-17	YoY(bps)
Raw Material Cost	45.4	45.5	45.7	42.0	49.4	394
Employee Expenses	8.5	9.7	8.5	11.0	9.5	100
Other Operating Expenses	19.1	18.3	21.8	24.0	19.3	20
Total Operating Cost	73.1	73.5	75.9	76.9	78.2	514

Welspun India

Income Statement

Period end (Rs mn)	Mar 16	Mar 17P	Mar 18E	Mar 19E
Net sales	59,239	66,405	72,437	83,395
<i>Growth (%)</i>	<i>11.7</i>	<i>12.1</i>	<i>9.1</i>	<i>15.1</i>
Operating expenses	-43,312	-50,572	-56,718	-64,965
Operating profit	15,927	15,834	15,719	18,430
Other operating income	0	0	0	0
EBITDA	15,927	15,834	15,719	18,430
<i>Growth (%)</i>	<i>25.0</i>	<i>(0.6)</i>	<i>(0.7)</i>	<i>17.3</i>
Depreciation	-3,718	-5,054	-5,243	-5,393
Other income	904	806	846	888
EBIT	13,113	11,585	11,322	13,925
Finance cost	-2,368	-1,583	-1,326	-1,058
Exceptional & extraordinary	0	-4,648	0	0
Profit before tax	10,745	5,355	9,996	12,867
Tax (current + deferred)	-3,254	-1,731	-2,999	-3,860
P / L form discount. Op.	0	0	0	0
Profit / (Loss) for period	7,491	3,624	6,997	9,007
P/L of Ass., Min Int, Pref Div	-52	0	0	0
Reported Profit / (Loss)	7,440	3,624	6,997	9,007
Adjusted net profit	7,440	8,271	6,997	9,007
<i>Growth (%)</i>	<i>37.8</i>	<i>11.2</i>	<i>-15.4</i>	<i>28.7</i>

Balance Sheet

Period end (Rs mn)	Mar 16	Mar 17P	Mar 18E	Mar 19E
Share capital	1,005	1,005	1,005	1,005
Reserves & surplus	18,696	22,967	28,196	34,928
Shareholders' funds	19,701	23,972	29,201	35,933
Minority Interests and others	412	355	355	355
Non-current liabilities	21,181	24,682	26,767	25,264
Long-term borrowings	17,922	20,160	22,088	20,416
Other non-current liabilities	3,259	4,521	4,679	4,848
Current liabilities	24,198	24,275	21,232	20,750
ST borrow, Curr maturity	14,556	13,793	9,566	7,626
Other current liabilities	9,641	10,482	11,667	13,124
Total (Equity and Liab)	65,491	73,283	77,555	82,302
Non-current assets	37,515	38,991	40,836	39,608
Fixed assets (Net block)	33,508	35,713	37,440	36,081
Non-current Investments	39	29	29	29
Long-term loans and adv	1,292	694	764	840
Other non-current assets	2,677	2,555	2,603	2,659
Current assets	27,976	34,292	36,720	42,693
Cash & Current investment	1,490	2,857	1,971	2,126
Other current assets	26,486	31,435	34,748	40,568
Total (Assets)	65,491	73,283	77,555	82,302
Total debt	32,478	33,953	31,654	28,042
Capital employed	55,850	62,801	65,889	69,178

Cash Flow Statement

Period end (Rs mn)	Mar 16	Mar 17P	Mar 18E	Mar 19E
Profit before tax	10,745	5,355	9,996	12,867
Depreciation	3,718	5,054	5,243	5,393
Change in working capital	-3,287	-3,278	-2,120	-4,357
Total tax paid	-2,567	-891	-2,999	-3,860
Others	2,368	1,583	1,326	1,058
Cash flow from oper. (a)	10,977	7,823	11,446	11,101
Capital expenditure	-11,177	-7,259	-6,970	-4,034
Change in investments	1,135	-972	1,229	0
Others	-699	54	-81	-90
Cash flow from inv. (b)	-10,741	-8,177	-5,823	-4,123
Free cash flow (a+b)	237	-355	5,623	6,978
Equity raised/(repaid)	0	0	0	0
Debt raised/(repaid)	1,627	1,475	-2,299	-3,612
Dividend (incl. tax)	-1,558	-786	-1,768	-2,275
Others	-2,315	50	-1,213	-936
Cash flow from fin. (c)	-2,246	740	-5,280	-6,824
Net chg in cash (a+b+c)	-2,009	385	343	154

Key ratios

Period end (%)	Mar 16	Mar 17P	Mar 18E	Mar 19E
Adjusted EPS (Rs)	7.4	8.2	7.0	9.0
<i>Growth (%)</i>	<i>37.8</i>	<i>11.2</i>	<i>(15.4)</i>	<i>28.7</i>
CEPS (Rs)	11.1	13.3	12.2	14.3
Book NAV/share (Rs)	19.6	23.9	29.1	35.8
Dividend/share (Rs)	1.3	0.7	1.5	1.9
Dividend payout ratio	20.9	21.7	25.3	25.3
EBITDA margin	26.9	23.8	21.7	22.1
EBIT margin	22.1	17.4	15.6	16.7
Tax rate	30.3	n/a	30.0	30.0
RoCE	25.4	19.5	17.6	20.6
Total debt/Equity (x)	1.6	1.4	1.1	0.8
Net debt/Equity (x)	1.5	1.3	1.0	0.7
Du Pont Analysis - ROE				
Net margin	12.6	12.5	9.7	10.8
Asset turnover (x)	1.0	1.0	1.0	1.0
Leverage factor (x)	3.6	3.2	2.8	2.5
Return on equity	43.7	37.9	26.3	27.7

Valuations


Period end (x)	Mar 16	Mar 17P	Mar 18E	Mar 19E
PER	13.4	10.7	13.5	10.5
PCE	8.9	6.6	7.7	6.6
Price/Book	5.0	3.7	3.2	2.6
Yield (%)	1.3	0.7	1.6	2.0
EV/EBITDA	8.2	7.5	7.9	6.5

Prerna Jhunjunwala
Research Analyst
 prerna.jhunjunwala@bksec.com
 +91-22-4031 7133


Nishant Agrawal
Research Analyst
 nishant.agrawal@bksec.com
 +91-22-4031 7185

B&K Universe Profile

By Market Cap (US\$ mn)



By Recommendation



B&K Securities is the trading name of Batlivala & Karani Securities India Pvt. Ltd.

B&K Investment Ratings.

	LARGE CAP (Market Cap > USD 2 bn)	MID CAP (Market Cap of USD 200 mn to USD 2 bn)	SMALL CAP (Market Cap < USD 200 mn)
BUY	>+20% (absolute returns)	>+25% (absolute returns)	>+30% (absolute returns)
OUTPERFORMER	+10% to +20%	+15% to +25%	+20% to +30%
UNDERPERFORMER	+10% to -10%	+15% to -15%	+20% to -20%
SELL	<-10% (absolute returns)	<-15% (absolute returns)	<-20% (absolute returns)

Disclaimer: This report was prepared, approved, published and distributed by Batlivala & Karani Securities India Private Limited (“B&K”) located outside of the United States (a “non-US Group Company”), which accepts responsibility for its contents. It is distributed in the U.S. by Enclave Capital, a U.S. registered broker dealer, on behalf of B&K, only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the “Exchange Act”)) pursuant to the exemption in Rule 15a-6. Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. (“FINRA”) or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization. Outside the United States, this report is distributed by B&K or an authorized affiliate of B&K.

The report has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. B&K has not verified the factual accuracy, assumptions, calculations or completeness of the information. Accordingly, B&K accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such Information or (iv) any action resulting therefrom. B&K provides the information for the purpose of the intended recipient’s analysis and review and recipients are advised to verify the factual accuracy, assumptions, calculations and completeness of the information.

This report was produced by B&K solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions. This document does not constitute an offer of, or an invitation by or on behalf of B&K or its affiliates or any other company to any person, to buy or sell any security.

Analyst Certification: Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

Disclosures, applying to B&K and the Analyst (together with associates and family members)

Ownership interest in the issuer of the securities mentioned	< 1%
Other financial interest in the issuer	None
Other material conflict of interest	None
Compensation/benefits received from issuer/3rd Parties in past 12 months:	
Public offerings managed/co-managed for issuer	None
Fees for merchant banking, investment banking or brokerage services (as percentage of issuer’s turnover)	< 0.1%
Compensation for other services (as percentage of issuer’s turnover)	< 0.1%
Analyst service as officer, director or employee of the issuer	None
Involvement in market-making in the issuer’s securities	None

Important US Regulatory Disclosures on Subject Companies

1. B&K or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.
2. B&K or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. B&K or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more person of B&K or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.
5. B&K or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
6. As of the publication of this report, Enclave Capital does not make a market in the subject securities.

Enclave Capital is the distributor of this document in the United States of America. Any US customer wishing to effect transactions in any securities referred to herein or options thereon should do so only by contacting a representative of Enclave Capital and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital (19 West 44th Street, suite 1700, New York, NY 10036. Tel No: (646) 454 8600).

B & K SECURITIES INDIA PRIVATE LTD.

Equity Research Division: City Ice Bldg., 298, Ground/1st Floor, Perin Nariman Street, Behind RBI, Fort, Mumbai - 400 001, India. Tel.: 91-22-4031 7000, Fax: 91-22-2263 5020/30.

Registered Office: Room No. 3/4, 7 Lyons Range, Kolkata - 700 001. Tel.: 91-33-2243 7902.

SEBI Registration No. for Batlivala & Karani Securities India Pvt. Ltd. (Research Entity) is INH300000211

B&K Research is also available on Bloomberg <BNKI>, Thomson First Call & Investext.